SCHEMBL19260599

SCHEMBL19260599

CNc1c2ccccc2nc2cc(OCCCN3CC(F)C3)c(OC)cc12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 10/20 0.47
DNMT1 P26358 4/20 0.47
SRC P12931 4/20 0.45
MAP2K1 Q02750 4/20 0.45
ABL1 P00519 3/20 0.45
EGFR P00533 3/20 0.45
FLT1 P17948 3/20 0.45
KDR P35968 3/20 0.45
SYK P43405 1/20 0.45
EHMT1 Q9H9B1 1/20 0.43
RAF1 P04049 1/20 0.43
MAPK3 P27361 1/20 0.43
MAPK1 P28482 1/20 0.43
TLR9 Q9NR96 1/20 0.43
TLR7 Q9NYK1 1/20 0.43
NSD2 O96028 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19260640 0.94 EHMT2 (0.53) EHMT2DNMT1SRCMAP2K1ABL1
SCHEMBL19260747 0.94 EHMT2 (0.53) EHMT2DNMT1SRCMAP2K1ABL1
SCHEMBL20720636 0.94 EHMT2 (0.53) EHMT2DNMT1SRCMAP2K1ABL1
Formic Acid SCHEMBL19260793 0.89 EHMT2 (0.51) EHMT2DNMT1SRCMAP2K1ABL1
SCHEMBL19260688 0.87 EHMT2 (0.56) EHMT2DNMT1SRCEHMT1TLR9
SCHEMBL20720605 0.86 SPIN1 (0.56) EHMT2DNMT1SRCEHMT1TLR9
SCHEMBL19260768 0.86 EHMT2 (0.51) EHMT2DNMT1TLR9TLR7NSD2
SCHEMBL19260783 0.86 EHMT2 (0.51) EHMT2DNMT1TLR9TLR7NSD2
SCHEMBL19260538 0.85 MAP2K1 (0.61) SRCMAP2K1ABL1EGFRFLT1
SCHEMBL20720709 0.84 EHMT2 (0.51) EHMT2DNMT1SRCABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 US claimed
EP-3416963-A1 HISTONE METHYLTRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2018-12-26 EP claimed
WO-2017142947-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-08-24 WO claimed
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-02-21 US disclosed
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 US disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 EP disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 EHMT2 2/4885DNMT1 32/4885SRC 3937/4885
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 EHMT2 2/4885DNMT1 24/4885SRC 3805/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 EHMT2 2/4885DNMT1 32/4885SRC 3937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.